In the face of the COVID-19 pandemic which has taken the world by storm, the lack of approved treatments targeted towards coronavirus has left physicians worldwide grappling with the situation. To help them navigate the black box of COVID-19 management, the ACP* has released a behemoth 28-chapter guide to arm physicians in the virus-infested battle field.
Acne is a common skin problem seen in primary care. Dr Wong
Soon Tee of Assurance Skin Clinic at Mt Elizabeth Novena Hospital, Singapore
shares his insights with Pearl Toh on how to manage acne in the primary care
Post hoc analyses of the LIBERTY AD SOLO 1 & 2* and ADOL** trials demonstrated significant reductions in pruritus, anxiety, and depression with dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis (AD).
Treatment with serlopitant helps lessen pruritus associated with mild-to-moderate psoriasis, results of a phase II trial have shown. This supports the continued development of serlopitant for this condition.
The oral TYK2/JAK1 inhibitor PF-06700841 appears to be effective in the treatment of patients with moderate-to-severe plaque psoriasis, with a tolerable safety profile, according to the results of a phase IIa study.
Treatment with baricitinib led to clinically meaningful improvements in itch and skin symptoms in patients with moderate-to-severe atopic dermatitis (AD), even in those with additional comorbid atopic conditions, according to a pooled analysis of two phase III studies released in the AAAAI 2020 Meeting.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.